150 related articles for article (PubMed ID: 28438772)
1. Severe vincristine-induced polyneuropathy in a teenager with anaplastic medulloblastoma and undiagnosed Charcot-Marie-Tooth disease.
Aghajan Y; Yoon JM; Crawford JR
BMJ Case Rep; 2017 Apr; 2017():. PubMed ID: 28438772
[TBL] [Abstract][Full Text] [Related]
2. Low dose vincristine-induced severe polyneuropathy in a Hodgkin lymphoma patient: a case report (vincristine-induced severe polyneuropathy).
Cil T; Altintas A; Tamam Y; Battaloğlu E; Isikdogan A
J Pediatr Hematol Oncol; 2009 Oct; 31(10):787-9. PubMed ID: 19770686
[TBL] [Abstract][Full Text] [Related]
3. Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Chauvenet AR; Shashi V; Selsky C; Morgan E; Kurtzberg J; Bell B;
J Pediatr Hematol Oncol; 2003 Apr; 25(4):316-20. PubMed ID: 12679647
[TBL] [Abstract][Full Text] [Related]
4. Charcot-Marie-Tooth disease type I diagnosed in a 5-year-old boy after vincristine neurotoxicity, resulting in maternal diagnosis.
Olek MJ; Bordeaux B; Leshner RT
J Am Osteopath Assoc; 1999 Mar; 99(3):165-7. PubMed ID: 10217912
[TBL] [Abstract][Full Text] [Related]
5. Treatment of high-risk medulloblastoma and other primitive neuroectodermal tumors with reduced dose craniospinal radiation therapy and multi-agent nitrosourea-based chemotherapy.
Prados MD; Wara W; Edwards MS; Ater J; Rabbit J; Lamborn K; Davis R; Levin VA
Pediatr Neurosurg; 1996 Oct; 25(4):174-81. PubMed ID: 9293544
[TBL] [Abstract][Full Text] [Related]
6. Vincristine neuropathy: neurophysiological and genetic studies in a case of Wilms tumor.
Schiavetti A; Frascarelli M; Uccini S; Novelli A
Pediatr Blood Cancer; 2004 Oct; 43(5):606-9. PubMed ID: 15382281
[TBL] [Abstract][Full Text] [Related]
7. Treatment-induced remission of medulloblastoma using a chemotherapeutic regimen devoid of vincristine in a child with Charcot-Marie-Tooth disease.
Bernstock JD; Cohen JL; Singh S; Schlappi CW; Fiveash JB; Johnston JM; Fequiere P; Orr BA; Li R; Friedman GK
Curr Oncol; 2019 Apr; 26(2):e266-e269. PubMed ID: 31043836
[TBL] [Abstract][Full Text] [Related]
8. Charcot-Marie-Tooth disease and vincristine.
Orejana-García AM; Pascual-Huerta J; Pérez-Melero A
J Am Podiatr Med Assoc; 2003; 93(3):229-33. PubMed ID: 12756314
[TBL] [Abstract][Full Text] [Related]
9. Vincristine treatment revealing asymptomatic hereditary motor sensory neuropathy type 1A.
Mercuri E; Poulton J; Buck J; Broadbent V; Bamford M; Jungbluth H; Manzur AY; Muntoni F
Arch Dis Child; 1999 Nov; 81(5):442-3. PubMed ID: 10519723
[TBL] [Abstract][Full Text] [Related]
10. Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy.
Beutler AS; Kulkarni AA; Kanwar R; Klein CJ; Therneau TM; Qin R; Banck MS; Boora GK; Ruddy KJ; Wu Y; Smalley RL; Cunningham JM; Le-Lindqwister NA; Beyerlein P; Schroth GP; Windebank AJ; Züchner S; Loprinzi CL
Ann Neurol; 2014 Nov; 76(5):727-37. PubMed ID: 25164601
[TBL] [Abstract][Full Text] [Related]
11. Vincristine exacerbates asymptomatic Charcot-Marie-tooth disease with a novel EGR2 mutation.
Nakamura T; Hashiguchi A; Suzuki S; Uozumi K; Tokunaga S; Takashima H
Neurogenetics; 2012 Feb; 13(1):77-82. PubMed ID: 22271166
[TBL] [Abstract][Full Text] [Related]
12. Adult medulloblastoma: multiagent chemotherapy.
Greenberg HS; Chamberlain MC; Glantz MJ; Wang S
Neuro Oncol; 2001 Jan; 3(1):29-34. PubMed ID: 11305414
[TBL] [Abstract][Full Text] [Related]
13. Fulminant peripheral neuropathy with severe quadriparesis associated with vincristine therapy.
Moudgil SS; Riggs JE
Ann Pharmacother; 2000 Oct; 34(10):1136-8. PubMed ID: 11054980
[TBL] [Abstract][Full Text] [Related]
14. Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life-threatening vincristine neurotoxicity.
Naumann R; Mohm J; Reuner U; Kroschinsky F; Rautenstrauss B; Ehninger G
Br J Haematol; 2001 Nov; 115(2):323-5. PubMed ID: 11703329
[TBL] [Abstract][Full Text] [Related]
15. Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia.
Nishikawa T; Kawakami K; Kumamoto T; Tonooka S; Abe A; Hayasaka K; Okamoto Y; Kawano Y
J Pediatr Hematol Oncol; 2008 Jul; 30(7):519-21. PubMed ID: 18797198
[TBL] [Abstract][Full Text] [Related]
16. Vincristine treatment triggering the expression of asymptomatic Charcot-Marie-Tooth disease.
Neumann Y; Toren A; Rechavi G; Seifried B; Shoham NG; Mandel M; Kenet G; Sharon N; Sadeh M; Navon R
Med Pediatr Oncol; 1996 Apr; 26(4):280-3. PubMed ID: 8600343
[TBL] [Abstract][Full Text] [Related]
17. Heterozygosity for CMT Type 4 Predicts a Severe Vincristine-induced Polyneuropathy Phenotype: A Case Report and Review of Literature.
Sy A; Cheng J; Cooper R; Mueller L
J Pediatr Hematol Oncol; 2019 Jan; 41(1):e41-e43. PubMed ID: 29877907
[TBL] [Abstract][Full Text] [Related]
18. Acute neurotoxicity following vincristine due to Charcot-Marie-Tooth disease in a young child with medulloblastoma.
Kissoon T; Gururangan S; Sladky J
Neurooncol Pract; 2019 May; 6(3):179-184. PubMed ID: 31385990
[TBL] [Abstract][Full Text] [Related]
19. Hereditary neuropathy with liability to pressure palsies emerging during vincristine treatment.
Kalfakis N; Panas M; Karadima G; Floroskufi P; Kokolakis N; Vassilopoulos D
Neurology; 2002 Nov; 59(9):1470-1. PubMed ID: 12427913
[No Abstract] [Full Text] [Related]
20. Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A.
Graf WD; Chance PF; Lensch MW; Eng LJ; Lipe HP; Bird TD
Cancer; 1996 Apr; 77(7):1356-62. PubMed ID: 8608515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
